首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1345439

全球神经调节设备市场 - 2023-2030

Global Neuro Modulation Devices Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

全球神经调节设备市场在 2022 年达到 54 亿美元，预计到 2030 年将达到 76 亿美元，2023-2030 年预测期间复合年增长率为 3.6%。

越来越多地采用有机策略（例如主要市场参与者进行收购以扩大其产品组合）等趋势预计将主导全球神经调节设备市场。

神经调节装置在美国被批准用于治疗运动障碍、癫痫、疼痛和抑郁症，并在标籤外用于其他神经系统适应症

神经刺激装置涉及将电极应用于大脑、脊髓或周围神经。这些精确放置的导线通过延长电缆连接到脉衝发生器和电源，从而产生必要的电刺激。低压电流从发生器传递到神经，可以抑制疼痛信号或刺激以前不存在的神经衝动。

此外，全球神经调节设备受到多种因素的推动，慢性疼痛和抑郁症等生活方式疾病的患病率上升、私人企业对神经疾病研发的投入增加以及神经系统疾病数量的增加是其中一些因素。驱动市场的因素。

此外，技术先进设备的采用、老年人口的激增以及对无创和微创手术需求的增长推动了行业的增长，主要参与者包括美敦力公司（Medtronic Plc）、雅培实验室（Abbott Laboratories）、波士顿科学公司（Boston Scientific Corp）、LivaNova Plc 和其他的

动力学

神经系统疾病患病率上升

神经系统疾病患病率的上升是预测期内帮助市场增长的关键因素之一。例如，根据世界卫生组织 2023 年更新的情况说明书，癫痫患病率上升，癫痫影响着全球约 5000 万人，使其成为最常见的神经系统疾病之一。近 80% 的癫痫患者居住在低收入和中等收入国家。据信，如果癫痫得到正确识别和治疗，高达 70% 的人可以摆脱癫痫发作。

癫痫症影响全球 500 万人，高收入国家每 10 万例中有 49 例，而低收入和中等收入国家的发病率更高，为每 10 万例 139 例。这是由于地方病、道路交通伤害、产伤和医疗基础设施变化的风险增加。近 80% 的癫痫患者生活在低收入和中等收入国家。

技术进步的崛起

主要参与者经常在研发上投入资金，以生产更新颖、更有效的神经调节设备。新的技术突破使得能够创造出更准确、侵入性更小的技术，从而改善患者的治疗结果。

此外，在过去的几年里，神经调节技术也取得了各种进展。这些发展的一些例子包括具有无线充电功能的可充电电池、编程的改进、门诊环境中侵入性较小的单阶段植入以及成本较低的新设备。

在过去的十年中，软件和硬件技术取得了显着进步，带来了重大的技术成功。硬件改进推动了软件实施和算法集成，而復杂的软件则实现了高效的大数据聚合和生物标记物发现。患者对现有技术的熟悉将促进数字健康与神经调节疗法的整合。有效解决方案的构建模块通常用于替代应用，例如用于医疗保健附加组件的智能手机和智能手錶。

关键参与者推出的产品数量增加

市场主要参与者推出的产品增多将有助于预测期内整体市场的增长。例如，2022 年 7 月，BioMed 和美敦力合作创建了 Orchestra BackBeat CNT，这是一种高度复杂的心臟神经调节疗法。它与多种抗高血压药物结合使用，其设计方式是自动运行，而不依赖于患者的依从性。此外，它可以简单地修改为利用标准植入物和引线安装技术与起搏器和其他心律控制设备一起使用。

此外，2022 年 1 月，美敦力 (Medtronic) 的 Intellis 和 Vanta 可充电神经刺激器设备获得 FDA 批准，用于治疗糖尿病周围神经病变 (DPN) 的慢性疼痛。 DPN 是一种进行性神经系统疾病，影响 30% 的糖尿病患者，导致麻木、烧灼感和剧烈疼痛。药物通常只能部分有效，并且可能导致严重的副作用。

神经调节手术的高成本

神经调节程序和设备的高成本是限制全球神经调节市场增长的主要因素，特别是在报销政策较差的发展中国家。标准植入式脉衝发生器的平均成本为 - 美元，植入手术的成本可能高达 25,000-35,000 美元。

脊髓刺激器设备的成本约为 13,000-40,000 美元。由于费用高昂且报销情况不佳，发展中国家能够负担得起神经系统治疗的患者非常有限。因此，医疗机构不愿意投资新的或技术先进的系统，从而限制了神经调节市场的增长。

Overview

Global Neuro Modulation Devices Market reached US$ 5.4 billion in 2022 and is expected to reach US$ 7.6 billion by 2030, growing with a CAGR of 3.6% during the forecast period 2023-2030.

The trend such as the increasing adoption of organic strategies such as acquisition by key market players to expand its product portfolio is expected to dominate the Global Neuromodulation Devices Market.

Neuromodulation devices are approved in the United States for the treatment of movement disorders, epilepsy, pain, and depression, and are used off-label for other neurologic indications

Neurostimulation devices involve the application of electrodes to the brain, the spinal cord or peripheral nerves. These precisely placed leads connect via an extension cable to a pulse generator and power source, which generates the necessary electrical stimulation. A low-voltage electrical current passes from the generator to the nerve and can either inhibit pain signals or stimulate neural impulses where they were previously absent.

Furthermore, the global neuromodulation devices are driven by various factors, the rise in the prevalence of lifestyle diseases such as chronic pain and depression, increased investment by private players for research and development of neurological disorders, and the increasing number of neurological diseases are some of the factors driving the market.

Moreover, the adoption of technologically advanced devices, the surge in the geriatric population, and the rise in demand for non-invasive and minimally invasive surgery fueled the industry growth having key players like Medtronic Plc, Abbott Laboratories, Boston Scientific Corp, LivaNova Plc and others

Dynamics

Rise in the Prevalence of Neurological Disorders

The rise in the prevalence of neurological disorders is one of the key factors that helps the market to grow during the forecast period. For instance, the rise in the Prevalence of Epilepsy according to the WHO updated factsheet 2023, Epilepsy affects around 50 million individuals worldwide, making it one of the most common neurological illnesses. Almost 80% of epileptics reside in low- and middle-income nations. It is believed that if epilepsy is correctly identified and treated, up to 70% of people can live seizure-free.

Epilepsy affects 5 million people globally, with high-income countries experiencing 49 per 100,000 cases, while low- and middle-income countries have a higher rate of 139 per 100,000. This is due to increased risks of endemic conditions, road traffic injuries, birth-related injuries, and variations in medical infrastructure. Nearly 80% of epilepsy patients live in low- and middle-income countries.

Rise in the Technological Advancements

Key players frequently spend in R&D to generate more novel and effective neuromodulation devices. New technical breakthroughs enable the creation of more accurate, less intrusive technologies that provide improved patient results.

For instance, in addition, in the last few years, there have been various developments in neuromodulation technology. Some of examples of these developments are rechargeable batteries with wireless charging, improvements in programming, less invasive single-stage implantation in outpatient settings, and lower-cost new devices.

Over the past decade, software and hardware technologies have advanced significantly, leading to significant technological successes. Hardware improvements have fueled software implementation and algorithmic integration, while sophisticated software enables efficient big data aggregation and biomarker discovery. Patients' familiarity with existing technology will facilitate the integration of digital health with neuromodulation therapies. The building blocks for effective solutions are often used in alternative applications, such as smartphones and smart watches for healthcare add-ons.

Rise in the Product Launches by Key Players

A rise in the product launches by key players in the market will help the overall market to grow during the forecast period. For instance, in July 2022 Orchestra BackBeat CNT, a highly sophisticated cardiac neuromodulation therapy, was created by collaboration between BioMed and Medtronic. It is combined with several antihypertensive drugs and is designed in a way that it operates automatically without depending on patient compliance. Furthermore, it can be simply modified to work with pacemakers and other cardiac rhythm control devices utilizing standard implant and lead installation techniques.

Additionally, in January 2022 Medtronic received FDA approval for its Intellis and Vanta rechargeable neurostimulator devices for treating chronic pain in diabetic peripheral neuropathy (DPN). DPN is a progressive neurological disorder affecting 30% of diabetes patients, causing numbness, burning, and severe pain. Medications are often only partially effective and can cause serious side effects.

High Cost of Neuromodulation Procedures

The high cost of neuromodulation procedures and devices is a major factor restraining the growth of the global neuromodulation market, especially in developing countries with poor reimbursement policies. The average cost of a standard implantable pulse generator is -USD implantation procedures can cost as high as USD 25,000-35,000.

Spinal cord stimulator devices cost around USD 13,000-40,000. Owing to high costs and a poor reimbursement scenario, a very limited pool of patients in developing countries can afford neurological treatment. As a result, healthcare facilities are reluctant to invest in new or technologically advanced systems, thus limiting the growth of the neuromodulation market.

Segment Analysis

The global neuromodulation devices market is segmented based on type, application, biomaterial, end user and region.

The Invasive Neuromodulation Segment From The Type Segment Accounted For Approximately 41.7% of Neuro Modulation Devices Share

The invasive neuromodulation segment from the type segment accounted for 41.7% and it is expected to be dominated during the forecast period. SCS devices deliver electrical pulses to the spinal cord to relieve chronic pain. They are often used as a treatment for failed back surgery syndrome, injuries to the spinal cord, complex regional pain syndrome, neuropathic pain, and ischemia-related refractory pain. The main benefits of the therapy are the decreased need for pain medication and overall improvement of the quality of life.

For instance, on April 19 2023 the company announced U.S. Food and Drug Administration (FDA) approval for Prospera, a spinal cord stimulation (SCS) system. The system features RESONANCE, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support.

Furthermore, in August 2022 Abbott announced that the U.S. Food and Drug Administration (FDA) has approved its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy. The next generation of Abbott's proprietary BurstDR stimulation, FlexBurst360 therapy offers pain coverage across up to six areas of the trunk and/or limbs and enables programming that can be adjusted as a person's therapeutic needs evolve.

Designed to fit within a person's life, the Proclaim Plus SCS system is recharge-free with a battery that can last up to 10 years.^ It can be used with Abbott's NeuroSphere Virtual Clinic connected care technology, which allows a person to both communicate with a physician through secure in-app video chat and remotely receive stimulation settings in real-time regardless of location.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the presence of major market players and huge pharmaceutical and biopharmaceutical industries, launches by key players, coupled with the rising investments in the country for the adoption of advanced technologies, an increasing number of patients suffering from neurological disorders, which is increasing the need for the adoption of neuromodulation devices, increased competition among market players, and significant expenditure on research and development.

On March 24, 2022, Medtronic plc, a global leader in healthcare technology, announced the first patient implants in the TITAN 2 pivotal study that will evaluate the safety and efficacy of Medtronic's investigational implantable tibial neuromodulation (TNM) device in people with overactive bladder (OAB). The minimally invasive technology stimulates the posterior tibial nerve near the ankle, transmitting electrical impulses that regulate the neural activity of the bladder.

For instance, in December 2022, Abbott announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system - the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches.

Competitive Landscape

The major global players in the market include Medtronic Plc, Abbott Laboratories, Boston Scientific Corp, LivaNova Plc , Integer Holdings Corporation, ElectroCore, Caputron, NeuroPce Inc, Nevro Corporation, BrainsWay and among others.

COVID-19 Impact Analysis

In the wake of the COVID-19 pandemic, the neurostimulation devices industry witnessed a major slump, due to the supply chain challenges and a limited workforce. Several non-emergency surgical procedures were also postponed during the initial months of the crisis.

Also, in the case of TMS, there was already enthusiastic interest in accelerated TMS protocols for depression before the emergence of COVID-19. During a pandemic, potential reductions in time to response, treatment time, and overall days of treatment with accelerated intermittent theta-burst stimulation (aiTBS), in comparison to standard TMS protocols, may have exciting implications for mitigating viral transmission risk as well as for increasing treatment accessibility.

By Type

Invasive Neuromodulation
- Spinal Cord Stimulation (SCS)
- Deep Brain Stimulation (DBS)
- Sacral Nerve Stimulation (SNS)
- Vagus Nerve Stimulation (VNS)
- Gastric Electric Stimulation (GES)

Non-Invasive Neuromodulation
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Transcranial Magnetic Stimulation (TMS)
- Respiratory Electrical Stimulation (RES)

By Application

Parkinson's Disease
Migraine
Epilepsy
Pain Management
Tremor
Others

By Biomaterial

Metallic Biomaterials
Polymeric Biomaterials
Ceramic Biomaterials

By End User

Hospitals
Ambulatory Surgical Centers
Specialized Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

In November 2022 CVRx-the developer of the world's first US Food and Drug Administration (FDA)-approved neuromodulation device to treat the symptoms of heart failure-has launched its new Barostim NEO2 implantable pulse generator (IPG). The second-generation device reduces the size of the IPG by 10% and extends battery life by 20%, reducing the frequency of device replacements for patients and their providers, a CVRx press release notes.
In July 2022, Helius Medical Technologies, Inc. received the United States Food and Drug Administration for its PoNSTM which provides electrical pulses to the tongue for use along with physical therapy as a short-term treatment for mild to moderate walking (gait) problems in people.
In July 2022, Abbott received the United States Food and Drug Administration (FDA) Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in treatment-resistant depression (TRD).

Why Purchase the Report?

To visualize the global neuro modulation devices market segmentation based on type, application, biomaterials, end user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of global neuro modulation devices market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The Global Neuro Modulation Devices Market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by Biomaterial
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in the Prevalence of Neurological Disorders
  - 4.1.1.2. Rise in the Technological Advancements
  - 4.1.1.3. Rise in the Product Launches by Key Players
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of Neuromodulation Procedures
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing Demand for Minimally Invasive Surgery in Developed Countries
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Invasive Neuromodulation*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Non-Invasive Neuromodulation

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Parkinson's Disease*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Migraine
8.4. Epilepsy
8.5. Pain Management
8.6. Tremor
8.7. Others

9. By Biomaterial

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Metallic Biomaterials *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Polymeric Biomaterials
9.4. Ceramic Biomaterials

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Ambulatory Surgical Centers
10.4. Specialized Clinics
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Medtronic Plc *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Abbott Laboratories
13.3. Boston Scientific Corp
13.4. LivaNova Plc
13.5. Integer Holdings Corporation
13.6. ElectroCore
13.7. Caputron
13.8. NeuroPce Inc
13.9. Nevro Corporation
13.10. BrainsWay

LIST NOT EXHAUSTIVE